Preclinical oncology drug development and validation services using tumor organoids and the HUB tumor organoid biobank



 
CrownBio exclusively provides preclinical oncology drug development and validation services using unique 3D organoid models developed using IP-protected Hubrecht Organoid Technology (HUB) protocols, as well as HUB’s biobank of already established patient-derived organoids (PDO).
Organoids have many benefits over conventional, 2D in vitro models, with the main feature being unprecedented predictivity of patient clinical response, compared with other systems. Organoids are highly physiologically relevant, multicellular structures which develop from stem or progenitor cells and exhibit remarkable similarities to in vivo organ architecture. They contain multiple differentiated cell lineages which interact and establish cell-cell contacts, replicating in vivo processes. As organoids are derived from stem cells, and maintained under specific culture conditions, they also recapitulate both original tissue genomic make up as well as displaying genomic stability over multiple passages in vitro.
 
These patient-derived, clinically-relevant models are developed direct from patient tissue (PDO) or already established and well-characterized PDX (PDX-derived organoids or PDXO) for expanded cancer indications, pharmacological, and mutational profiles. The resulting models are robust, and can be propagated and cryopreserved to establish biobanks, as well as resuscitated for repeat studies without compromising genetic identity. Overall, organoids provide the most translatable 3D in vitro models available for oncology drug development, which the clients utilize for large-scale drug screening and immunotherapy assessment.
 
 
 
 
 
CrownBio’s organoid screening packages enable clients to evaluate efficacy, select models, and assess combination strategies. Matrix, high throughput, library screening allows the simultaneous selection of lead candidates alongside the identification of target patient populations. Organoid efficacy screening provides multiple models across more than 15 indications (which recapitulate patient population heterogeneity) to quantitatively evaluate compound efficacy. Combination strategies can also be assessed to identify optimal dosing, with multiple combination strategies simultaneously tested. Using PDXO models for these studies allows enhanced transition from in vitro screening to in vivo validation with matched organoids and PDX models offering a range of patient-relevant mutational and pharmacological profiles.
 

HUB Tumor Organoids

Tumor organoids are developed directly from patient tumors and matched healthy tissue using patented and exclusive HUB technology. CrownBio’s well-characterized and ample patient-derived xenograft (PDX) collection is also available as an alternative source of human tumor tissue. PDX models allow additional tumor organoid development across more indications and to truly represent patient population diversity for biomarker identification and hypothesis generation

 

Key HUB Organoid Benefits

  • Improve the translatability of your 3D in vitro data with clinically relevant organoid models, which show unprecedented patient response predictivity
  • Benefit from faster development and enhanced scalability of organoids compared to in vivo translational oncology platforms
  • Model and mirror patient population diversity, via screening multiple tumor organoid models simultaneously
  • Access both tumor and healthy organoids to evaluate in vitro drug potency and efficacy as well as off target effects

Translational 3D In Vitro Models for Drug Development Studies

Choose from a rapidly expanding collection of patient-derived HUB organoids covering breast, colorectal, and pancreatic cancer from HUB’s established biobank.

HUB’s adult stem cell-derived organoids are developed from patient tumor as well as healthy tissue, using highly refined, proprietary culture methods originally developed in the Clevers Lab. Organoids developed using HUB’s protocols faithfully recapitulate original patient tissue histo- and molecular pathology and show high predictivity of patient response for your drug development studies.

Expand Tumor Indication Choice with PDX-Derived Organoids

Gain access to an expanded repertoire of cancer indications, mutational, and pharmacological profiles through PDX-derived organoids (PDXO), developed using HUB protocols.

 
For more information about Tumor Organoids, check out:

https://www.crownbio.com/oncology/hub-organoids/hub-organoids-for-drug-discovery

For any enquires, please contact us
 

 

Tags: Atlantis Bioscience, Biomarker discovery, CRO, Crown Bioscience, CrownBio, DMPK, drug development, drug discovery, homograft, Hubrecht Organoid Technology, humanised models, immuno-oncology, OmniScreen, organoids, Orthotopic Models, patient derived xenograft, PDX, pharmacokinetic, Preclinical Oncology, syngeneic models